Synopsis:
Recently listed Small-cap stock is in focus after Nomura funds Ireland bought a stake in the company through a bulk deal.
A Small-cap company that is engaged in the development, manufacturing, & commercialization of differentiated formulations, is in the spotlight today after Nomura funds Ireland bought a stake in the company through a bulk deal on October 16, 2025.
With a market capitalization of Rs. 10,151.09 crore, Rubicon Research Ltd is trading at Rs. 61 6, down by 1.92 percent from its previous close of Rs. 628.20 per equity share. The shares touched an intraday low of Rs. 615 in today’s trading session.
What’s the deal?
As per the latest bulk deal on NSE, Nomura Funds Ireland Plc, through Nomura Funds Ireland India Equity Fund, has acquired 16.5 lakh shares (representing a 1 percent stake) in Rubicon Research at Rs 616.31 per share, amounting to a total value of Rs 101.69 crore.
Also Read: ₹25,000 Cr Capex: Power stock jumps after reporting 133% YoY net profit growth
About the company
Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company specializing in the development, manufacturing, and commercialization of differentiated formulations.
As of June 30, 2025, the company had 72 approved ANDA and NDA products by the US FDA, with 66 already commercialized, contributing USD 195 million to the USD 2,455.7 million US generic pharmaceutical market in FY24. It also has 17 new products awaiting US FDA approval and 63 under various stages of development.
The company markets over 350 SKUs to 96 customers, including the three largest US wholesalers that handle over 90 percent of the market’s drug distribution, along with GPOs and pharmacy chains.
Internationally, Rubicon has filed or registered 48 products across markets like Australia, the UK, Singapore, Saudi Arabia, and the UAE, with commercialization expected post-approval.
It also offers contract manufacturing services in India, Australia, and New Zealand, operating three manufacturing facilities in India and two US FDA–inspected R&D centers in India and Canada.
With a price range of Rs. 461 to Rs. 485 per equity share, Rubicon Research Limited launched its initial public offering (IPO). The subscription period was open from October 9 to October 13, 2025.
On October 16, 2025, the company’s shares went public on the BSE and NSE platform, initially trading for Rs. 620 each. This indicated strong investor interest and represented a listing gain of about 27.84 percent over the upper end of the issue price.
It is trading at a price-to-earnings (P/E) ratio of 75.6x, which is higher than the industry average of 22.7x. A Debt to Equity of about 1.10 percent, return of equity (ROE) of 34.9 percent and a return on capital employed (ROCE) of about 28.6 percent demonstrate the company’s financial position.
Written by Akshay Sanghavi
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
